Drug · CHEMBL1671
PROPRANOLOL HYDROCHLORIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PROPRANOLOL HYDROCHLORIDE. Drugs and targets, record CHEMBL1671. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1671
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Anaprilin, Angilol, Apsolol, Avlocardyl, Bedranol, Bedranol s.r., Beprane, Berkolol, Beta-prograne mr, Betadur cr, Cardinol, Caridolol, Deralin, Dociton, Dupromex, Half beta-prograne mr, Half propanix la, Half propatard la, Half-beprane cr, Half-betadur cr, Half-inderal la, Hemangeol, Hemangiol, Inderal, Inderal la, Inderalici, Indobloc, Innopran, Innopran xl, Lederpronol, Lopranol la, Monoprolol, Obsidan, Probeta la, Propanix la, Propanix-10, Propanix-160, Propanix-160 sr, Propanix-40, Propanix-80, Propatard la, Propranolol hydrochloride intensol, Pylapron, Rapranol sr, Sagittol, Slo-blok, Slo-pro, Sloprolol, Sumial, Syprol, Tesnol
- ChEMBL
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | Beta-1 adrenergic receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/153 |
| ADRB2 | Beta-2 adrenergic receptor | Beta-2 adrenergic receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/154 |
Source ChEMBL
Diseases20
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 20Source Open Targets
See all 20 diseasesTrials24
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04299438 | Propranolol Rescue of Prolonged Labor | Phase 3 | 164 | 2023-08-23 | propranolol hydrochloride | Its name | ClinicalTrials.gov |
| NCT03152786 | Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Phase 2 | 46 | 2025-02-17 | propranolol hydrochloride | Its name | ClinicalTrials.gov |
| NCT00902161 | A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED) | Phase 1 | 22 | 2012-05-08 | propranolol hydrochloride | Its name | ClinicalTrials.gov |
| NCT01988831 | Efficacy of Propranolol Treatment to Prevent Melanoma Progression | Phase 2 | 450 | propranolol hydrochloride | Its name | ClinicalTrials.gov | |
| NCT07125391 | Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer | Phase 2 | 136 | propranolol hydrochloride | Its name | ClinicalTrials.gov | |
| NCT00647816 | Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg | Phase 1 | 100 | propranolol hydrochloride | Its name | ClinicalTrials.gov | |
| NCT00647608 | Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg | Phase 1 | 98 | propranolol hydrochloride | Its name | ClinicalTrials.gov | |
| NCT06787066 | Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms | Early phase 1 | 75 | propranolol hydrochloride | Its name | ClinicalTrials.gov | |
| NCT05219799 | Sex Disparities in Hypoxic Vasodilation and Impact of Obesity | Early phase 1 | 72 | propranolol hydrochloride | Its name | ClinicalTrials.gov | |
| NCT00864747 | A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions | Phase 1 | 60 | propranolol hydrochloride | Its name | ClinicalTrials.gov |
1 to 10 of 24
See all 24 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Propranolol vs Placebo: Postpartum Hemorrhage | 17 of 84 | 8 of 80 | 164 | NCT04299438 | Trial comparisons |
| Propranolol vs Placebo: Mode of Delivery | 48 of 84 | 46 of 80 | 164 | NCT04299438 | Trial comparisons |
| Propranolol vs Placebo: Chorioamnionitis | 18 of 84 | 24 of 80 | 164 | NCT04299438 | Trial comparisons |
| Propranolol vs Placebo: Neonatal Morbidity | 7 of 84 | 4 of 80 | 164 | NCT04299438 | Trial comparisons |
| Propranolol vs Placebo: Maternal Morbidity | 10 of 84 | 5 of 80 | 164 | NCT04299438 | Trial comparisons |
| Propranolol vs Placebo: deaths from any cause | 0 of 84 | 0 of 80 | 164 | NCT04299438 | Trial comparisons |
| Propranolol vs Placebo: serious adverse events | 3 of 84 | 1 of 80 | 164 | NCT04299438 | Trial comparisons |
| Group I (Propranolol Hydrochloride) vs Group II (no Treatment): deaths from any cause | 0 of 23 | 0 of 23 | 46 | NCT03152786 | Trial comparisons |
| Group I (Propranolol Hydrochloride) vs Group II (no Treatment): serious adverse events | 0 of 23 | 0 of 23 | 46 | NCT03152786 | Trial comparisons |
Papers from its trials2
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1671
GET https://conductscience.org/api/drugs/v1/CHEMBL1671/trials?page=2